XBiotech Inc. - Common Stock (NQ:XBIT)

2.310 -0.040 (-1.70%)

Streaming Delayed Price Updated: 11:04 AM EST, Nov 26, 2025 Add to My Watchlist

Price and Volume

Volume	24,587
Open	2.370
Bid (Size)	2.310 (100)
Ask (Size)	2.330 (100)
Prev. Close	2.350
Today's Range	2.310 - 2.370
52wk Range	2.090 - 7.640
Shares Outstanding	30,436,964
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm

January 13, 2025

From The Schall Law Firm

Via Business Wire

XBiotech Pauses Rheumatology program

December 23, 2024

Findings from recently completed Rheumatoid Arthritis Study raise questions

From XBiotech Inc.

Via GlobeNewswire

Performance

YTD	-44.6%	-44.6%
1 Month	-10.1%	-10.1%
3 Month	-34.0%	-34.0%
6 Month	-22.0%	-22.0%
1 Year	-66.3%	-66.3%

More News

XBIT Stock Earnings: XBiotech Reported Results for Q2 2024 ↗

August 12, 2024

Via InvestorPlace

What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? ↗

June 18, 2024

Via Benzinga

XBIT Stock Earnings: XBiotech Reported Results for Q1 2024 ↗

May 13, 2024

Via InvestorPlace

XBIT Stock Earnings: XBiotech Reported Results for Q4 2023 ↗

March 18, 2024

Via InvestorPlace

Stocks That Hit 52-Week Lows On Thursday ↗

October 20, 2022

Via Benzinga

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

June 18, 2024

From XBiotech Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 22, 2024

Via Benzinga

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

January 04, 2024

From XBiotech Inc.

Via GlobeNewswire

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

November 14, 2023

From XBiotech Inc.

Via GlobeNewswire

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

September 26, 2023

From XBiotech Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 05, 2023

Via Benzinga

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

August 30, 2023

From XBiotech Inc.

Via GlobeNewswire

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

August 08, 2023

From XBiotech Inc.

Via GlobeNewswire

FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

May 22, 2023

From XBiotech Inc.

Via GlobeNewswire

Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 17, 2023

Via Benzinga

Dow Jumps Over 100 Points; US Housing Starts Rise In April ↗

May 17, 2023

Via Benzinga

XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares

May 17, 2023

From XBiotech Inc.

Via GlobeNewswire

XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

April 17, 2023

From XBiotech Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Monday ↗

November 28, 2022

Via Benzinga

XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer

October 13, 2022

From XBiotech Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Thursday ↗

September 22, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

September 20, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

September 19, 2022

Via Benzinga

Frequently Asked Questions

Is XBiotech Inc. - Common Stock publicly traded?

Yes, XBiotech Inc. - Common Stock is publicly traded.

What exchange does XBiotech Inc. - Common Stock trade on?

XBiotech Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for XBiotech Inc. - Common Stock?

The ticker symbol for XBiotech Inc. - Common Stock is XBIT on the Nasdaq Stock Market

What is the current price of XBiotech Inc. - Common Stock?

The current price of XBiotech Inc. - Common Stock is 2.310

When was XBiotech Inc. - Common Stock last traded?

The last trade of XBiotech Inc. - Common Stock was at 11/26/25 11:04 AM ET

What is the market capitalization of XBiotech Inc. - Common Stock?

The market capitalization of XBiotech Inc. - Common Stock is 70.31M

How many shares of XBiotech Inc. - Common Stock are outstanding?

XBiotech Inc. - Common Stock has 70M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.